EMulate Therapeutics

Our CEO, Chris Rivera, recently spoke with @PM360online about the leadership lessons he’s learned throughout his career and what he believes sets up a company for success. Click here to read the article: bit.ly/3HnC8kx

#HappyNewYear from EMulate! We wish everyone a year filled with joy, happiness, and good health!

#HappyHolidays from our team here at EMulate! We would like to wish everyone a happy and healthy holiday season, from our family to yours.

Our CEO, Chris Rivera and VP, Preclinical Development, Xavier Figueroa, Ph.D. spoke with Pharma’s Almanac about our disruptive technology and how it may help usher in a true digital transformation in healthcare. Read more on what they had to say here: bit.ly/3HTZ0Kr

Our CEO, Chris Rivera, spoke with @LongevityTech to discuss EMulate’s #technology and how it emulates drugs without using harsh chemicals, as well as several advantages that may help you live a healthier, longer life. Click here to read more: bit.ly/3GDA0Xi

Recently, we announced the publication of positive preclinical data evaluating the use of EMulate’s wearable device that uses WAV files to deliver low to ultra-low radio frequency energy in validated murine models of pain. More on the data here: bit.ly/3yMy9KL

EMulate Therapeutics today announced the formation of a new technology advisory committee that will bring expertise across multiple disciplines to facilitate company growth and innovation. To learn more details on the committee, click here: bit.ly/3rxj8bH

EMulate Therapeutics was recently named a top 10 emerging company at the forefront of providing therapeutics services in The Life Sciences Review Magazine (@lifesciencesrev), August 2022 Therapeutics Edition. To view the August edition, click here: bit.ly/3r0ukxl

We are now on Twitter! EMulate Therapeutics is a clinical-stage therapeutic device company, utilizing radio frequency energy (RFE) technology to treat unmet medical needs. Follow us for corporate and clinical updates, and visit our website to learn more: bit.ly/3Uz3cTD